Insight Molecular Diagnostics (IMDX) Capital Leases (2016 - 2019)

Insight Molecular Diagnostics has disclosed Capital Leases across 4 years of filings, most recently posting $100000.0 for Q2 2019.

• Capital Leases for Q2 2019 came in at $100000.0, down 34.21% year-over-year; the trailing twelve-month figure through Jun 2019 was $100000.0 (down 34.21% YoY), and the FY2018 annual result was $187000.0, down 35.29% from the prior year.
• Capital Leases came in at $100000.0 for Q2 2019 at Insight Molecular Diagnostics, down from $134000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $400000.0 in Q2 2017 to a low of $100000.0 in Q2 2019.
• The 4-year median for Capital Leases is $211000.0 (2016), against an average of $222615.4.
• Across the five-year window, Capital Leases soared 79.5% in 2017 and slumped 62.0% in 2018, its largest moves.
• Insight Molecular Diagnostics' Capital Leases stood at $161000.0 in 2016, then jumped by 79.5% to $289000.0 in 2017, then tumbled by 35.29% to $187000.0 in 2018, then slumped by 46.52% to $100000.0 in 2019.
• The last three Capital Leases figures came in at $100000.0 (Q2 2019), $134000.0 (Q1 2019), and $187000.0 (Q4 2018), per Business Quant data.